Clinical Trial

Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary

Name: Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary — clinical trial record (NCT07434180)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: Lu-FAP CUP

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The aim of the study is to test if a new radionuclide therapy, called 177-Lu-FAP-2286, works to treat cancer in patients with Cancer of Unknown Primary (CUP).

Trial Details

NCT Number	NCT07434180
Lead Sponsor	Peter MacCallum Cancer Centre, Australia Collaborators: National Health and Medical Research Council, Australia, Novartis, SOFIE, University of Melbourne
Conditions	Cancer of Unknown Primary
Enrollment	20 participants
Start Date	2026-06
Primary Completion	2030-06 (estimated)
Study Completion	2030-06 (estimated)
Updated on ClinicalTrials.gov	2026-02-25